BPC 157 and TB-500

BPC-157 and TB-500 are the two most-combined peptides in the recovery and healing space. Together they form the "Wolverine Blend" sold by dozens of clinics and compounding pharmacies. Here is what each peptide actually does, why they are combined, and what the research supports.

The two peptides, side by side

Before getting into why the combination is popular, it helps to understand what each peptide actually is, because they are often conflated in peptide marketing. BPC-157 and TB-500 are unrelated molecules with distinct origins and distinct mechanisms — they are combined specifically because their mechanisms do not overlap.

Why combine them?

The mechanistic rationale for combining BPC-157 and TB-500 is complementary rather than redundant action. BPC-157 appears to work primarily at the site of injury — stimulating new blood vessel formation, activating local repair signaling, and enhancing the migration and attachment of repair cells to the damaged area. TB-500, by contrast, is proposed to work more systemically, promoting cell migration across tissues by modulating the actin cytoskeleton. Cells migrate toward injury sites using their actin machinery; TB-500 appears to improve that machinery's function.

The two peptides therefore address different halves of the same problem. BPC-157 creates a favorable local repair environment (more blood vessels, more growth signals, less inflammatory nitric oxide). TB-500 improves the supply of cells that can migrate into that environment to do the repair work. Neither mechanism is proven in controlled human trials, and both are extrapolations from preclinical and in-vitro data, but the logic is internally consistent — which is part of why the combination has become so widespread.

The Wolverine Blend

When clinics and compounding pharmacies sell a "Wolverine Blend" or "Wolverine protocol," they are typically selling BPC-157 and TB-500 in a single injectable vial. The most common ratios are 10 mg BPC-157 / 10 mg TB-500 (in combined 20 mg vials) or 5 mg / 5 mg (10 mg combined vials). Some formulations add other peptides — GHK-Cu (copper peptide, for additional tissue repair signaling), KPV (an anti-inflammatory tripeptide), or thymosin alpha-1 — but the BPC/TB base is the defining feature.

The "Wolverine" name itself is discussed in detail on the Wolverine peptide page. The short version: it is a generic nickname referencing the Marvel character's healing factor, used widely across peptide vendors and not owned as a trademark by any single company.

BPC 157 and TB-500 dosing in combination protocols

The dosing protocols cited most often for the BPC-157 + TB-500 combination are:

Two things about these protocols are worth understanding. First, the weekly TB-500 dosing is an order of magnitude higher than the weekly BPC-157 dosing because TB-500 is used at mg-per-week levels while BPC-157 is dosed in hundreds of micrograms per day. This reflects the different potencies and different proposed mechanisms. Second, the protocols are community-derived — they are not from a published clinical trial, because no such trial exists for this combination. The dosing numbers have accumulated through peptide-forum conventions, compounding pharmacy recommendations during the years these peptides were being prepared under §503A, and anecdotal titration by users.

BPC 157 vs TB-500 — which is better?

This is one of the most-searched questions about the two peptides, and the honest answer depends entirely on what you are trying to accomplish. The most straightforward summary:

• For local tendon, ligament, or joint injury, BPC-157 alone has more preclinical data and is more commonly cited in the tissue-repair literature.
• For systemic recovery or multi-tissue injury — for example, recovering from overtraining, multi-joint chronic inflammation, or cardiac tissue concerns — TB-500's systemic action profile is the more targeted choice.
• For gut-related indications (IBS, leaky gut, colitis, ulcers), BPC-157 is dramatically more studied than TB-500 and is the obvious primary choice. See the gut health page.
• For combined indications or when the injury scope is unclear, the Wolverine Blend combination is the default community choice because it covers both action profiles.

The practical reality is that users in peptide communities rarely pick one over the other; the combination has become the default because the peptides are viewed as mechanistically complementary and because the combined cost is close to the sum of the individual peptides.

Safety and regulatory reality of the combination

Combining BPC-157 and TB-500 does not reduce the regulatory or safety caveats of either peptide — if anything, it compounds them. Both are on the WADA Prohibited List (BPC-157 under S0 Non-Approved Substances, TB-500 under S2 Peptide Hormones). Neither is FDA-approved. Both are implicated by the FDA Category 2 bulk drug list's general concerns about peptide compounding safety. Neither has been studied for long-term human safety, and the combination specifically has never been tested in a controlled human trial.

The angiogenesis concern discussed on the side effects page applies to both peptides individually and may be more pronounced in combination. Both peptides promote vascular and cellular activity that, in the wrong context, could theoretically support tumor progression. This is an unresolved concern, not a documented outcome, but it is the main reason cautious clinicians recommend against the combination for general wellness use in patients with any cancer history.

Frequently asked questions